Cargando…
Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694359/ https://www.ncbi.nlm.nih.gov/pubmed/36422537 http://dx.doi.org/10.3390/ph15111407 |
_version_ | 1784837780047659008 |
---|---|
author | Tsai, Jeng-Shiuan Wei, Sheng-Huan Chen, Chian-Wei Yang, Szu-Chun Tseng, Yau-Lin Su, Po-Lan Lin, Chien-Chung Su, Wu-Chou |
author_facet | Tsai, Jeng-Shiuan Wei, Sheng-Huan Chen, Chian-Wei Yang, Szu-Chun Tseng, Yau-Lin Su, Po-Lan Lin, Chien-Chung Su, Wu-Chou |
author_sort | Tsai, Jeng-Shiuan |
collection | PubMed |
description | The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy or radiotherapy in programmed death-ligand 1 high expressors remain limited. This study aimed to retrospectively compare the treatment efficacy of the therapies by studying 47 patients with treatment-naïve advanced NSCLC who received ICI monotherapy (n = 28) or combination therapy either with chemotherapy or radiotherapy (n = 19). Progression-free survival (PFS) and OS were estimated using the Kaplan–Meier method and compared using log–rank tests. It was observed that patients who received combination therapy had a better PFS than monotherapy, but no such significant benefit was observed in OS. The difference in PFS was higher in the subgroup of patients with low neutrophil-to-lymphocyte ratio (NLR) than in the high-NLR patient subgroup. This study suggests that pembrolizumab in combination with chemotherapy or radiotherapy could provide a significant benefit in PFS, especially in patients with treatment-naïve advanced NSCLC with low NLR. Furthermore, our study also demonstrates the potential use of NLR as a biomarker for prediction of treatment outcomes in patients with advanced NSCLC receiving combination therapy. |
format | Online Article Text |
id | pubmed-9694359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96943592022-11-26 Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio Tsai, Jeng-Shiuan Wei, Sheng-Huan Chen, Chian-Wei Yang, Szu-Chun Tseng, Yau-Lin Su, Po-Lan Lin, Chien-Chung Su, Wu-Chou Pharmaceuticals (Basel) Article The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy or radiotherapy in programmed death-ligand 1 high expressors remain limited. This study aimed to retrospectively compare the treatment efficacy of the therapies by studying 47 patients with treatment-naïve advanced NSCLC who received ICI monotherapy (n = 28) or combination therapy either with chemotherapy or radiotherapy (n = 19). Progression-free survival (PFS) and OS were estimated using the Kaplan–Meier method and compared using log–rank tests. It was observed that patients who received combination therapy had a better PFS than monotherapy, but no such significant benefit was observed in OS. The difference in PFS was higher in the subgroup of patients with low neutrophil-to-lymphocyte ratio (NLR) than in the high-NLR patient subgroup. This study suggests that pembrolizumab in combination with chemotherapy or radiotherapy could provide a significant benefit in PFS, especially in patients with treatment-naïve advanced NSCLC with low NLR. Furthermore, our study also demonstrates the potential use of NLR as a biomarker for prediction of treatment outcomes in patients with advanced NSCLC receiving combination therapy. MDPI 2022-11-14 /pmc/articles/PMC9694359/ /pubmed/36422537 http://dx.doi.org/10.3390/ph15111407 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tsai, Jeng-Shiuan Wei, Sheng-Huan Chen, Chian-Wei Yang, Szu-Chun Tseng, Yau-Lin Su, Po-Lan Lin, Chien-Chung Su, Wu-Chou Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio |
title | Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio |
title_full | Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio |
title_fullStr | Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio |
title_full_unstemmed | Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio |
title_short | Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio |
title_sort | pembrolizumab and chemotherapy combination prolonged progression-free survival in patients with nsclc with high pd-l1 expression and low neutrophil-to-lymphocyte ratio |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694359/ https://www.ncbi.nlm.nih.gov/pubmed/36422537 http://dx.doi.org/10.3390/ph15111407 |
work_keys_str_mv | AT tsaijengshiuan pembrolizumabandchemotherapycombinationprolongedprogressionfreesurvivalinpatientswithnsclcwithhighpdl1expressionandlowneutrophiltolymphocyteratio AT weishenghuan pembrolizumabandchemotherapycombinationprolongedprogressionfreesurvivalinpatientswithnsclcwithhighpdl1expressionandlowneutrophiltolymphocyteratio AT chenchianwei pembrolizumabandchemotherapycombinationprolongedprogressionfreesurvivalinpatientswithnsclcwithhighpdl1expressionandlowneutrophiltolymphocyteratio AT yangszuchun pembrolizumabandchemotherapycombinationprolongedprogressionfreesurvivalinpatientswithnsclcwithhighpdl1expressionandlowneutrophiltolymphocyteratio AT tsengyaulin pembrolizumabandchemotherapycombinationprolongedprogressionfreesurvivalinpatientswithnsclcwithhighpdl1expressionandlowneutrophiltolymphocyteratio AT supolan pembrolizumabandchemotherapycombinationprolongedprogressionfreesurvivalinpatientswithnsclcwithhighpdl1expressionandlowneutrophiltolymphocyteratio AT linchienchung pembrolizumabandchemotherapycombinationprolongedprogressionfreesurvivalinpatientswithnsclcwithhighpdl1expressionandlowneutrophiltolymphocyteratio AT suwuchou pembrolizumabandchemotherapycombinationprolongedprogressionfreesurvivalinpatientswithnsclcwithhighpdl1expressionandlowneutrophiltolymphocyteratio |